Afrocab has developed a FAQ (below) that covers the topics of PrEP and explains how CAB-LA works, is taken, and its side effects.
Cabotegravir Long-Acting Injectable for Prevention
Frequently Asked Questions
Diversity, Equity and Access to HIV Research
On May 2, 2024, AVAC staffer Jessica Salzwedel gave a presentation on diversity, equity and access in HIV research at the Ending the HIV Epidemic Conference at Weill Cornell Medicine. Check out the full presentation in PDF format.
“When we think about what engagement is important for research, it involves building systems of trust.” – Jessica Salzwedel
The Years Ahead in Biomedical HIV Prevention Research
This graphic shows the updated status of large-scale prevention trials through the end of 2024.
Media Science Cafes
AVAC Capability Statement
Since 2012, AVAC has worked to strengthen the capacity of journalists to report on HIV prevention research and global health and science topics. Through its flagship Media Science Café Program, AVAC partners with health media associations in Kenya, Malawi, Tanzania, Uganda, Zambia and Zimbabwe to connect journalists with subject matter experts—researchers, policymakers and advocates—and help build the relationships needed to foster accurate and informed reporting of HIV, COVID and emerging health and science issues.
Advocacy to Accelerate Prevention R&D for Sexually Transmitted Infections
AVAC Case for Support
AVAC accelerates the development and delivery of STI prevention options by fostering collaborations with STI and HIV research advocates, developing new STI vaccines and diagnostics, and creating tools to monitor STI research and investment activities.
Allocation of Non-Commercial CAB for PrEP Supply in Low- and Middle-Income Countries, 2023-2025
HIV Vaccine and Antibody Efficacy Trials to Date
This infographic provides a comprehensive overview of HIV vaccine and antibody efficacy trials. Over 20 years and 12 trials, only two positive signals have been observed.
Avac Event
Just What is Discovery Medicine? And What Does it Mean for HIV Vaccine Research?
Participants joined to gain a broad understanding of Discovery Medicine including an overview of the current landscape for HIV vaccines. We also discussed what it means for HIV vaccine research and development moving forward, with a focus on community and advocacy priorities.
Speakers:
- Dr. Betty Mwesigwa, Makerere University Walter Reed Project
- Tian Johnson, BRILLIANT HIV Vaccine Discovery Consortium
- Dr. Cathy Slack, HIV AIDS Vaccines Ethics Group
- Dr. Sandhya Vasan, Henry M. Jackson Foundation for the Advancement of Military Medicine, US Military HIV Research Program
Moderators:
- Stacey Hannah, AVAC
- Louis Shackelford, HIV Vaccine Trials Network (HVTN) & COVID-19 Prevention Network (CoVPN)
Recording / Full Slides / Resources
Avac Event
PrEP and the Role of HIV Self-Testing
HIV self-testing (HIVST) is a safe, accurate, and effective alternative to provider-administered testing that many users prefer for its convenience and confidentiality. At IAS 2023, WHO issued a new recommendation to offer HIVST for PrEP initiation and continuation as an innovative way to increase PrEP access and coverage and further simplify PrEP delivery. However, many implementers still have questions on how to effectively roll out and scale up this important self-care intervention.
On May 23, AVAC and WHO hosted a webinar to learn more about WHO guidance on use of HIVST and to hear directly from a panel of experts on their experiencing rolling out HIVST for PrEP, guidance on procurement and costing, and more.
Recording / Slides
For Us by Us: PrEP in Black America – A Master Plan for HIV Prevention in Black America
In the spirit of seeking change to ameliorate the devastating impact of HIV in Black communities through biomedical HIV prevention, Black leaders convened the “PrEP in Black America (PIBA) Summit” virtually and in person on September 13, 2022, in Atlanta, Georgia. Attendees have included Black activists, researchers, scientists, providers, and policymakers from across the country representing more than 50 organizations. Following the event, PIBA generated a report summarizing the event and key recommendations entitled, “For Us by Us: PrEP in Black America – A Master Plan for HIV Prevention in Black America.”